Nida Zahra Naqvi, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 500 Upper Chesapeake Dr, Bel Air, MD 21014 Phone: 443-643-1500 Fax: 443-643-1505 |
Anushruti S. Sharma, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 500 Upper Chesapeake Dr, Upper Chesapeake Medical Services, Bel Air, MD 21014 Phone: 410-643-1500 Fax: 443-643-1505 |
Bijay Risal, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 500 Upper Chesapeake Dr, Bel Air, MD 21014 Phone: 443-643-1500 Fax: 443-643-1505 |
Kathy Mcgill, DO Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 500 Upper Chesapeake Dr, Bel Air, MD 21014 Phone: 443-643-1500 Fax: 443-643-1505 |
Dr. Angelita Estadilla, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 500 Upper Chesapeake Dr, Bel Air, MD 21014 Phone: 443-643-1500 Fax: 443-643-1505 |
Sukrita Sheshu Mysore, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 500 Upper Chesapeake Dr, Bel Air, MD 21014 Phone: 443-643-1500 |
Mrs. Krishnaveni Bupathi, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 500 Upper Chesapeake Dr, Bel Air, MD 21014 Phone: 443-643-1500 |
Murugesan Manivasagam, CRNP Hospitalist Medicare: Medicare Enrolled Practice Location: 500 Upper Chesapeake Dr, Bel Air, MD 21014 Phone: 443-643-1500 Fax: 443-643-1505 |
News Archive
"Oregon's hospital spending boom is winding to a close," as hospitals cut back on projects, Portland Business Journal reports. "Portland-area hospitals have opened, started construction on, or announced expansions costing at least $1.3 billion in the past 18 months. Projects include cancer treatment centers, cardiac units and pediatric care facilities.
Becoming overweight at a young age can trigger a molecular chain reaction that leads some girls to experience puberty early, according to new research published in Nature Communications.
Pharmaceuticals, Inc. today announced interim results of a randomized, openālabel, active-control multicenter Phase 2 study of oral ridaforolimus, an investigational mTOR inhibitor, in patients with metastatic or recurrent endometrial cancer. Based on this interim analysis, the study demonstrated a statistically significant improvement in the primary endpoint of median progression-free survival (PFS) in patients receiving single-agent ridaforolimus compared to patients receiving standard-of-care treatment.
Digoxin, a drug commonly used to treat heart conditions, was associated with a 71 percent higher risk of death and a 63 percent higher risk of hospitalization among adults with diagnosed atrial fibrillation and no evidence of heart failure, according to a Kaiser Permanente study that appears in the current online issue of Circulation: Arrhythmia and Electrophysiology.
› Verified 2 days ago